E-viri
Recenzirano
Odprti dostop
-
Rautio, Katrina, M.D; Tapanainen, Juha S., M.D., Ph.D; Ruokonen, Aimo, M.D., Ph.D; Morin-Papunen, Laure C., M.D., Ph.D
Fertility and sterility, 2007, 2007-Jan, 2007-01-00, 20070101, Letnik: 87, Številka: 1Journal Article
In a randomized, placebo-controlled study, we studied the effects of 4 months’ treatment with rosiglitazone on low-grade inflammation, liver function, lipid levels, and blood pressure in 30 overweight women with polycystic ovary syndrome. Rosiglitazone significantly decreased serum C-reactive protein levels, white blood cell count, and alanine aminotransferase enzyme activity but did not affect lipid or blood pressure levels. Placebo had no effect on any parameters.
